Evidence map›Paper›PMID 36316443›Full record

ArticleOncogene2022

Extracellular vesicles-transferred SBSN drives glioma aggressiveness by activating NF-κB via ANXA1-dependent ubiquitination of NEMO.

Han Chen, Xuhong Chen, Zhuojun Zhang, Wenhao Bao, Zhiqing Gao, Difeng Li, Xiaoyi Xie, Ping Zhou, Chunxiao Yang, Zhongqiu Zhou and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 2 countries.

Han Chen *Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Xuhong Chen *Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Science, Guangzhou Medical University, Guangzhou, 511436, China.
Zhuojun Zhang *Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Wenhao Bao *Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Zhiqing GaoAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Difeng LiAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Xiaoyi XieAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Ping ZhouAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Chunxiao YangAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Zhongqiu ZhouMeishan Women and Children's Hospital, Alliance Hospital of West China Second University Hospital, Sichuan University, Meishan, 620000, China.
Jinyuan PanDepartment of oncology, Huanggang Central Hospital of Yangtze University, Huanggang, 438000, China.
Xiangqin KuangAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Ruiming TangThe Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou, 511518, China.
Zhengfu FengThe Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou, 511518, China.
Lihuan ZhouThe Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou, 511518, China.
Dachun ZhuDepartment of Operating Room, Shenzhen Baoan Women's and Childiren's Hospital, Shenzhen, 518000, China.
Jianan YangAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.ORCID 0000-0002-1369-836X
Lan WangDepartment of Pathogen Biology and Immunology, School of Basic Courses, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Hongbiao HuangAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.ORCID 0000-0002-9873-0559
Daolin TangDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX, 75390, USA.ORCID 0000-0002-1903-6180
Jinbao LiuAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China. jliu@gzhmu.edu.cn.ORCID 0000-0003-2220-2407
Lili JiangAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China. jianglili@gzhmu.edu.cn.ORCID 0000-0003-2361-5975
Guangzhou Medical University · CNGuangzhou Medical University Cancer Hospital · CNGuangdong Pharmaceutical University · CNShenzhen Bao'an District People's Hospital · CNSichuan University · CNSouthern University of Science and Technology · CNSouthwestern Medical Center · USYangtze University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioma is the most common malignant primary brain tumor with aggressiveness and poor prognosis. Although extracellular vesicles (EVs)-based cell-to-cell communication mediates glioma progression, the key molecular mediators of this process are still not fully understood. Herein, we elucidated an EVs-mediated transfer of suprabasin (SBSN), leading to the aggressiveness and progression of glioma. High levels of SBSN were positively correlated with clinical grade, predicting poor clinical prognosis of patients. Upregulation of SBSN promoted, while silencing of SBSN suppressed tumorigenesis and aggressiveness of glioma cells in vivo. EVs-mediated transfer of SBSN resulted in an increase in SBSN levels, which promoted the aggressiveness of glioma cells by enhancing migration, invasion, and angiogenesis of recipient glioma cells. Mechanistically, SBSN activated NF-κB signaling by interacting with annexin A1, which further induced Lys63-linked and Met1-linear polyubiquitination of NF-κB essential modulator (NEMO). In conclusion, the communication of SBSN-containing EVs within glioma cells drives the formation and development of tumors by activating NF-κB pathway, which may provide potential therapeutic target for clinical intervention in glioma.

Indexed as

Extracellular VesiclesGliomaAnnexin A1Antigens, DifferentiationCell Line, TumorHumansI-kappa B KinaseNeoplasm ProteinsNF-kappa BUbiquitinationAnnexin A1Antigens, DifferentiationANXA1 protein, humanI-kappa B KinaseIKBKG protein, humanNeoplasm ProteinsNF-kappa BSBSN protein, human

Identifiers

PMID36316443
OpenAlexW4307848033

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.